Application of glucocorticoid in preparation of medicine for treating and/or preventing respiratory virus infection

A glucocorticoid and virus infection technology, applied in the treatment of respiratory virus infection, can solve problems such as death and organ damage in patients with new coronary pneumonia, and achieve the effect of reducing mortality, no toxic side effects, and high safety

Pending Publication Date: 2021-12-31
THE INST OF BASIC MEDICAL SCI OF CHINESE ACAD OF MEDICAL SCI
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the super-inflammation formed by the excessive activation of monocyte-macroph...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of glucocorticoid in preparation of medicine for treating and/or preventing respiratory virus infection
  • Application of glucocorticoid in preparation of medicine for treating and/or preventing respiratory virus infection
  • Application of glucocorticoid in preparation of medicine for treating and/or preventing respiratory virus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] Example 1. Dexamethasone can promote macrophages to clear SARS-CoV-2Delta strains in vitro

[0058] 1. Experimental steps

[0059] Get alveolar macrophages of normal ICR mice, spread them in 24-well plate according to 5x10^4 cells per hole, and infect SARS-CoV-2Delta strain virus (the virus is obtained from Institute of Medical Experimental Animals, Chinese Academy of Medical Sciences), after 2 hours of infection, discard the medium, wash twice with PBS, discard the PBS for the last time, add 1mL dexamethasone to each well, so that the final concentrations are 0.2uM and 1uM respectively , continue to culture for 22h or 46h, then wash twice with PBS, discard the PBS for the last time, add 1mL TRIZOL (Invitrogen Company, catalog number 15596026) to each well, extract RNA according to the instructions of the kit, and use High-Capacity cDNA Reverse Transcription Kit with RNase Inhibitor Kit (Applied Biosystems, 4374967) for reverse transcription. The copy numbers of vir...

Embodiment 2

[0063] Example 2. Dexamethasone can down-regulate the expression of IL-6 in macrophages infected by Delta strain in vitro

[0064] 1. Experimental steps

[0065] Take mouse alveolar macrophages as described in Example 1, spread 5x10^4 cells per well in a 24-well plate, and infect SARS-CoV-2Delta strain virus according to 2.5x10^4 TCID50 the next day, after 2 hours of infection , discard the medium, wash twice with PBS, and discard the PBS for the last time, add 1mL dexamethasone to each well to make the final concentrations 0.2uM and 1uM respectively, continue to culture for 22h or 46h, and then wash twice with PBS , discard the PBS for the last time, add 1mL TRIZOL (Invitrogen Company, 15596026) to each well, extract RNA according to the instructions of the kit, and use the High-Capacity cDNA ReverseTranscription Kit with RNase Inhibitor Kit (Applied Biosystems Company, 4374967). box for reverse transcription. The expression of IL-6 was analyzed by qPCR. The primers used...

Embodiment 3

[0069] Example 3. Dexamethasone can down-regulate the expression of cathepsin L in alveolar macrophages

[0070] 1. Experimental steps

[0071] Take mouse alveolar macrophages as described in Example 1, spread them in a 24-well plate according to 5x104 cells per well, and infect SARS-CoV-2Delta strain virus according to 2.5x104 TCID50 the next day, after 30 minutes of infection , Discard the culture medium, wash twice with PBS, discard the PBS for the last time, add 1mL dexamethasone to each well to make the final concentration of 0.2uM and 1uM respectively, continue to culture for 30min or 4h, and then wash two times with PBS For the last pass, discard the PBS, add 1 mL TRIZOL (Invitrogen, 15596026) to each well, extract RNA according to the instructions of the kit, and use the High-Capacity cDNA Reverse Transcription Kit with RNase Inhibitor (Applied Biosystems, 4374967). Perform reverse transcription. Cathepsin L expression was analyzed by qPCR. The primers used are li...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of glucocorticoid in preparation of a medicine for treating and/or preventing respiratory virus infection. The respiratory viruses are selected from SARS-CoV virus, SARS-CoV-2 virus, Middle East respiratory syndrome coronavirus, influenza virus, measles virus, parotitis virus, respiratory syncytial virus, parainfluenza virus, human metapneumovirus, Hendea virus, Nipie virus, rubella virus, rhinovirus, adenovirus, reovirus, coxsackie virus and ECHO virus.

Description

technical field [0001] The present invention relates to the field of treatment of respiratory virus infection. Specifically, the present invention relates to the use of glucocorticoids in the preparation of medicines for treating and / or preventing respiratory viral infections. Background technique [0002] Viral pneumonia is lung inflammation caused by upper respiratory tract virus infection and downward spread. It can occur throughout the year, but it is mostly seen in winter and spring, and can be outbreaks or sporadic epidemics. The main clinical manifestations are fever, headache, body aches, dry cough and pulmonary infiltration. The occurrence of viral pneumonia is related to the virulence of the virus, the route of infection, the age of the host, and the state of immune function. Respiratory tract infection is one of the leading causes of death worldwide, especially in severe pneumonia patients with high mortality and severe sequelae. The main viruses that cause vi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/58A61K31/573A61K31/57A61K31/56A61K9/72A61P11/00A61P31/12A61P31/14A61P31/16A61P31/20
CPCA61K31/58A61K31/573A61K31/57A61K31/56A61K9/0043A61P11/00A61P31/12A61P31/14A61P31/16A61P31/20
Inventor 黄波
Owner THE INST OF BASIC MEDICAL SCI OF CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap